Banco Santander’s Alexion Pharmaceuticals ALXN Stock Holding History

Banco Santander’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,023	Closed	-$804K	–	409
2020 Q3	$804K	Buy	7,023 +4,755	+210%	+$513K	0.01%	253
2020 Q2	$255K	Buy	+2,268	New	+$241K	﹤0.01%	321
2020 Q1	–	Sell	-6,598	Closed	-$714K	–	467
2019 Q4	$714K	Buy	6,598 +761	+13%	+$81.4K	0.01%	299
2019 Q3	$572K	Buy	5,837 +1,550	+36%	+$175K	0.01%	303
2019 Q2	$562K	Sell	4,287 -28,706	-87%	-$3.7M	0.01%	299
2019 Q1	$4.46M	Hold	32,993	–	–	0.05%	145
2018 Q4	$3.21M	Buy	32,993 +1,293	+4%	+$153K	0.04%	172
2018 Q3	$4.41M	Sell	31,700 -482,207	-94%	-$60.5M	0.05%	160
2018 Q2	$63.8M	Buy	513,907 +1,119	+0.2%	+$131K	0.74%	11
2018 Q1	$57.2M	Buy	512,788 +424,088	+478%	+$50.7M	0.67%	21
2017 Q4	$10.6M	Hold	88,700	–	–	0.15%	59
2017 Q3	$12.4M	Buy	+88,700	New	+$12.1M	0.21%	62

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Banco Santander's ALXN Position: Q4 2020 in Review

Banco Santander sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 7,023 shares — an estimated $804K sold.

Banco Santander first reported a position in ALXN in Q3 2017 and held it in 12 quarters. The position peaked at $63.8M in Q2 2018. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Banco Santander reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Banco Santander sold 7,023 Alexion Pharmaceuticals shares in Q4 2020, an estimated $804K.
Banco Santander first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 12 quarters.
Banco Santander's Alexion Pharmaceuticals position peaked at $63.8M in Q2 2018.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Banco Santander's 13F filing for Q4 2020, filed 12 Feb 2021.